An interventional study of Tai Chi Intervention Group and Usual Care and Health Education in Head and Neck Neoplasms and Cancer-related Fatigue, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by West China Hospital · Not applicable, Interventional, and Supportive care
Among 19 studies in Head and Neck Neoplasms by West China Hospital — 10 open to participants now, 11 under way, 2 of them phase 3. Head and Neck Neoplasms · West China Hospital.
Among the 19 studies in Head and Neck Neoplasms by West China Hospital, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 7 that started in 2026, is one of 3 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 19th registered.
2,713 studies on the registry are indexed under Head and Neck Neoplasms; 596 are open to participants now.
Browse Head and Neck Neoplasms studies →10 of the 19 studies in Head and Neck Neoplasms by West China Hospital are open now, in 1 country. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 18–80
West China Hospital · Sites in China
Ages 18–75
West China Hospital · Sites in China
Ages 18–65
West China Hospital · Sites in China
Ages 18–80
West China Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 453 Head and Neck Neoplasms studies recruiting now, 345 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 21 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 2
First in 2020; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 116 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 40 across the 17 interventional studies, 12 across the 2 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
West China Hospital is the lead sponsor of 501 studies on the registry; 246 are open to participants now.
7 of the studies in Head and Neck Neoplasms by West China Hospital that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07353671Phase 3West China HospitalTopical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis | 2026-12-31 |
| NCT07467083Phase 3West China HospitalDevelopment and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy | 2027-03-01 |
| NCT07635277West China HospitalAkkermansia Muciniphila (AKK) for Radiation-Induced Skin Injury | 2026-11-30 |
| NCT07704372West China HospitalSuperoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer | 2027-01-31 |
| NCT07583914West China HospitalSafety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 19 studies in Head and Neck Neoplasms by West China Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, randomized controlled study will evaluate whether a Tai Chi exercise program can help reduce cancer-related fatigue in patients with head and neck cancer undergoing radiotherapy.
A total of 116 participants will be randomly assigned in a 1:1 ratio to either a Tai Chi intervention group or a control group. Participants in the Tai Chi group will receive usual cancer care together with a 12-week Yang-style 16-form Tai Chi program. The exercise program will begin during radiotherapy preparation and will be adjusted according to the participant's treatment phase and physical condition. Participants in the control group will receive usual care, health education, and activity recording.
The primary outcome is the change in cancer-related fatigue from baseline to within 7 days after completion of radiotherapy, measured using the Brief Fatigue Inventory (BFI) global score. The study will also assess fatigue at week 12 and functional exercise capacity using the 6-minute walk test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Tai Chi Intervention Group
Behavioral: Usual Care and Health Education
Participants will receive an approximately 12-week Yang-style 16-form Tai Chi program in addition to standardized usual care. The intervention will begin approximately 2 weeks before radiotherapy during the radiotherapy preparation period and will be delivered mainly through in-person group sessions led by a qualified Tai Chi instructor, with safety management provided by rehabilitation and medical staff. Each session will include warm-up, Yang-style 16-form Tai Chi practice, and cool-down. The intervention includes an introductory learning phase, a radiotherapy phase, and a post-radiotherapy consolidation phase. During radiotherapy, the exercise program may be adjusted according to the participant's physical condition and treatment-related symptoms, including changes in movement amplitude, pace, rest intervals, and training duration. Training intensity or duration may be reduced, or sessions may be temporarily suspended, when clinically indicated.
Participants will receive usual care, health education, and activity recording during the study period.
Change From Baseline in Brief Fatigue Inventory Global Score After Completion of Radiotherapy
Time frame: Baseline to within 7 days after the final radiotherapy session
Change From Baseline in Brief Fatigue Inventory Global Score at Week 12
Time frame: Baseline to Week 12
Change From Baseline in 6-Minute Walk Distance at Week 12
Time frame: Baseline to Week 12
EORTC QLQ-C30 Scores
Time frame: Baseline, within 7 days after the final radiotherapy session, and Week 12 after randomization
EORTC QLQ-H&N35 Scores
Time frame: Baseline, within 7 days after the final radiotherapy session, and Week 12 after randomization
Hospital Anxiety and Depression Scale Scores
Time frame: Baseline, within 7 days after the final radiotherapy session, and Week 12 after randomization
Distress Thermometer Score
Time frame: Baseline, within 7 days after the final radiotherapy session, and Week 12 after randomization
Radiotherapy Completion Rate
Time frame: Within 7 days after the final radiotherapy session
Overall Radiotherapy Treatment Time
Time frame: From the first radiotherapy session through the final radiotherapy session, approximately 6-6.5 weeks
Radiotherapy Interruption Days
Time frame: From the first radiotherapy session through the final radiotherapy session, approximately 6-6.5 weeks
Plan to share: No
Started Sep 2026 (actual). Primary completion is estimated for Nov 2027, 14 months after the start.
Of 437 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 14 months is below that.
Counting every sponsor, half of 455 studies reached it within 32 months; a quarter within 18 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.